FELIZ Y PRÓSPERO 2014
HAPPY AND PROSPEROUS 2014

para todos nuestros Clientes y Amigos...

Muchas gracias por compartir este 2013,

y los invitamos a trabajar juntos en un 2014

AÚN MEJOR !!!

to all our Customers and Friends...

Thank you very much for sharing 2013,

and we invite you to work together in a 2014

EVEN BETTER !!!

Mails: msg.latam@gmail.com   -   medinacasabella@alumni.gwu.edu

Phone: 0054-11-3532-0510 (office)   -   0054-911-4420-5103 (mobile)

https://www.facebook.com/MSG.LatAm

https://twitter.com/MSGLatAm

https://twitter.com/MedinaCasabella

http://ar.linkedin.com/in/medinacasabella 

MEyGC 2014 - CEU en MANAGEMENT ESTRATÉGICO y GESTIÓN DEL CAMBIO (UTN)

Link:  http://www.sceu.frba.utn.edu.ar/cursosfooter/gestion/curso-de-extension-universitaria-en-management-estrategico-y-gestion-del-cambio.html

GOSyF 2014 - CEU en GESTIÓN DE ORGANIZACIONES DE SALUD y FARMA (UTN)
Link: http://www.sceu.frba.utn.edu.ar/cursosfooter/gestion/gestion-de-organizaciones-de-salud-y-farma.html

Pharma Trends: Predictions for 2014-2015

by Jon Wetzel

To look forward we need to first look back.  From 2008-2012 we saw big pharma collide creating larger companies.  Genentech-Roche, Novartis-Alcon, Pfizer-Wyeth and GlaxoSmithKline-Human Genome Sciences just to name a few. 

During this same time frame the economies of the world have seen crashes and upheavals causing some of these same companies to “trim” their workforces.  What does all this mean for 2013-2015?

Economic worries will hold Operation Excellence in check for big pharma 2013-2015

I would love to say that all these companies are going to hire Lean and Six Sigma teams to help improve their efficiencies and decrease costs.  The reality is that I don’t see this happening.

With the economies of the world still not at a firm footing large pharmaceutical companies will continue to play it safe.  This means not investing heavily into departments that don’t have an immediate positive impact on their scientific or drug pipelines.

They will also still be wrestling with fusing their larger organizations together while deciding which divisions to either sell off or shut down.

Upside – Biotech will be ripe for OpEx

Either through acquisitions or strategic partnerships big pharma will be eyeing biotechs to help fill their drug pipeline.  Biotech companies are going to need to be lean and efficient if they hope to be considered a possible target by the larger pharma companies.

Smaller biotechs will be looking for outside consultants to help them clean up their operations.  Larger biotechs will look to bolster their existing programs or begin implementing new Operational Excellence Programs from the ground up.

A bumper crop of solid Biotechs 2013 – 2015

Emerging over the next 12-24 months will be biotech companies that are focused, efficient and “eye catching”.  They will be filled with innovative and forward thinking employees that are able to decrease costs while improving their organizations.

Expect 2014 and 2015 to be filled with larger pharmaceutical companies gobbling up these same biotechs and incorporating them into their larger organizations.

Change is in the air…and change is good if you’re a biotech company.

Fuente: Pharma IQ

Haciendo click en los links siguientes, accederán a los Contenidos de algunos de nuestros CURSOS A MEDIDA:

Programa Ejecutivo en PENSAMIENTO ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/04/programa-ejecutivo-en-pensamiento.html

Programa Ejecutivo en MANAGEMENT ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/04/programa-ejecutivo-en-management.html

Programa Ejecutivo en GESTIÓN DEL CAMBIO

http://msg-latam-meic.blogspot.com.ar/2014/04/programa-ejecutivo-en-gestion-del.html

Taller de ESTRATEGIAS EFECTIVAS para ESCENARIOS TURBULENTOS

http://msg-latam-meic.blogspot.com.ar/2014/04/taller-de-estrategias-efectivas-para.html

Por dictado IN COMPANY, consultar al mail: msg.latam@gmail.com

ó al +5411-3532-0510

Pharma Trends: Global Medicine Spending to Pass $1 Trillion in 2014

by Gerald Clarke

This year will mark a milestone in the pharmaceutical industry’s growth as drug sales will exceed $1 Trillion. This was the finding of IMS Health in their new report on the spending on pharmaceuticals and trends that will affect it between now and 2017.

Two factors will be the major drivers of this growth, increased spending on medicines in emerging markets and increased spending on new drugs for cancer and orphan diseases.

Diverging Growth Engines

In the developed world, the picture is more complicated than a simple growth story. Factors increasing spending on pharmaceuticals include the appearance of new drugs for various diseases such as cancer and an increasingly aged population. The Affordable Care Act (Obamacare) could potentially also increase pharma spending as previously uninsured people gain coverage. However some of this trend is counteracted by blockbusters dropping off patent, causing many to move to cheaper generics. Additionally the global financial crisis has caused many governments to look for areas to cut spending and as we have covered before, many of them are looking towards their medicines spend.

Emerging markets

China more than any other country will be a main driver of growth with a CAGR of 14-17% until 2017. The country aims to have total healthcare coverage of its 1.35 billion population by the year 2020 which could mean over $180 billion in growth over the 4 year period. In countries such as China, it is likely to be the increased take-up of generic medicines which will drive growth.

Biologics/new drugs

In developed nations it will be the new innovative medicines such as cancer drugs and biologics driving growth with IMS predicting that spending on specialty medicines will grow from $171 billion in 2012 to $230 billion by 2017.

Overall

For the first time in over 50 years last year, the spending on pharmaceuticals fell as many drugs fell off the patent cliff. The future predicted by IMS Health however, is cautiously optimistic; spending in developed nations will grow, just at a reduced rate. It appears that innovation on the home front and penetration into emerging markets will be the main drivers behind growth in the coming years, but a question to ask might be what about long term?

$1 Trillion Dollars at a Glance

Bio-Based Manufacturing $1.2 Trillion

Arms Industry $1.7 Trillion

B2C eCommerce $1.298 Trillion

GDP of Mexico $1.17 Trillion

Years required to earn $1.2 Trillion at US minimum wage ($7.25/hr) 79,500,000 years.

Fuente: Pharma IQ


Haciendo click en el link de abajo, accederás a los Contenidos del

Programa Ejecutivo en PENSAMIENTO ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/03/programa-ejecutivo-en-pensamiento.html

INICIA Lunes 21 de Abril de 2014 en UTN, Universidad Tecnológica Nacional

Consultar por opción IN COMPANY a: msg.latam@gmail.com